Search results
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
Zacks via Yahoo Finance· 6 hours agoNovavax (NVAX) closed the most recent trading day at $14.06, moving +1.99% from the previous trading...
The FDA Now Wants Fall COVID Vaccines to Target KP.2—But Not All Manufacturers Can Pivot
Verywell Health via Yahoo News· 4 hours agoLess than a week after telling COVID-19 vaccine manufacturers to target the JN.1 variant this fall,...
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
Zacks via Yahoo Finance· 3 days agoNovavax (NVAX) seeks FDA???s approval to update its COVID-19vaccine for the 2024-2025 fall season...
A Synergy Of Excellence: Novavax-Mabion Partnership During Unprecedented Times Amid The Covid-19...
BioresearchOnline· 21 hours agoNovavax's COVID-19 vaccine, Nuvaxovid, was developed in record time with the support of Mabion, a...
Novavax’s South African Phase IIb COVID-19 vaccine trial likely to reveal results within next...
Pharmaceutical Technology via Yahoo Finance· 3 days agoSouth Africa’s existing regulatory, consent and ethics frameworks around HIV vaccine trial investigations helped with regards to quick initiation and straightforward progress ...
FDA modifies strain recommendation for fall COVID vaccine amid variant shifts, uptick in cases
Center for Infectious Disease Research and Policy· 6 days agoOn June 5, the FDA's vaccine advisory group recommended a switch to the JN.1 variant, though it held...
Is It Too Late to Buy Novavax Stock? | The Motley Fool
The Motley Fool· 7 days agoNovavax (NVAX -4.32%) stock is suddenly a buy again this year, with its stock price more than...
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
Fox News· 6 days agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update...
FDA asks COVID vaccine makers to target KP.2 strain, if feasible, for next shot
Reuters via Yahoo News· 6 days agoThe Food and Drug Administration's change in recommendation, in an update dated Thursday, comes even...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 10 hours agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...